Akebia Therapeutics Inc.
AKBA
Get informed when a big investor buys or sells
+ FollowMarket Cap$359.47M
Close$
$-2.55
309.1% downside
Current Fair Value
309.1% downsideOvervalued by 309.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $359.47 Million |
|---|---|
| Enterprise Value | $213.81 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.02 |
| Beta | 0.24 |
| Outstanding Shares | 267,046,755 |
Return
| Return on Equity | -74.93% |
|---|---|
| Return on Assets | -5.66% |
| Return on Invested Capital | -1.56% |
Valuation & Multiples
| P/E Ratio | -17.38 |
|---|---|
| PEG | 7 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.92 |
| Enterprise Value to EBIT | -72.55 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$51.67 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$53.25 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6749▼ 42.02% |
|---|---|
| Total Calls | 518,300▲ 43.26% |
| Total Puts | 349,800▼ 11.71% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 39.55%▼ 5.22% |
|---|---|
| Total Invested | $141.41M▼ 37.00% |
| Investors Holding | 177▲ 3.00% |
ESG Score
No data
About Akebia Therapeutics Inc.
CEO: John Butler